RLMD
Relmada Therapeutics, Inc.
$7.03
+0.69
(+10.88%)
Mkt Cap
515.54M
Volume
1,449,894
52W Range
0.48-8
Sector
Healthcare
Beta
0.43
EPS (TTM)
-1.11
P/E Ratio
-3.32
Revenue (TTM)
0
Rev Growth (5Y)
N/A
EPS Growth (5Y)
N/A
Company Description
Relmada Therapeutics, Inc., a clinical-stage biotechnology company, focuses on developing various products for the treatment of central nervous system (CNS) diseases and other disorders. Its lead product candidate is Esmethadone (d-methadone, dextromethadone, and REL-1017), a new chemical entity and N-methyl-D-aspartate receptor antagonist that is in Phase 3 clinical trials for the adjunctive or monotherapy treatment of major depressive disorder in adults. The company was founded in 2004 and is headquartered in Coral Gables, Florida.
Track Record
Showing latest 4 periods • Swipe for more
| Metric | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Net Income | (57.39M) | (79.98M) | (98.79M) | (157.04M) | (125.75M) | (59.46M) | (15.01M) | (17.32M) | (8.96M) | (6.29M) | (2.98M) | (20.80M) |
| EPS | -1.45 | -2.65 | -3.28 | -5.30 | -7.16 | -3.81 | -1.63 | -2.74 | -2.86 | -2.08 | -1.03 | -8.37 |
| Free Cash Flow | (45.79M) | (51.76M) | (51.66M) | (103.80M) | (91.87M) | (27.81M) | (12,092) | (10.50M) | (6.01M) | (6.52M) | N/A | N/A |
| FCF / Share | -1.16 | -1.72 | -1.72 | -3.50 | -5.23 | -1.78 | -0.00 | -1.66 | -1.92 | -2.16 | N/A | N/A |
| Operating CF | (45.79M) | (51.76M) | (51.66M) | (103.80M) | (91.87M) | (27.81M) | (12,092) | (10.50M) | (6.00M) | (6.47M) | N/A | N/A |
| Total Assets | 94.00M | 45.82M | 97.55M | 152.91M | 223.33M | 118.19M | 117.14M | 10.22M | 3.05M | 2.84M | N/A | N/A |
| Total Debt | 0 | 0 | 0 | 0 | 0 | 0 | 110,247 | 364,204 | 2.94M | 276,670 | N/A | N/A |
| Cash & Equiv | 3.50M | 3.86M | 4.09M | 5.40M | 44.44M | 2.50M | 36.28M | 9.22M | 2.24M | 1.71M | N/A | N/A |
| Book Value | 86.51M | 35.52M | 85.36M | 140.44M | 208.26M | 105.58M | 115.68M | 7.61M | (5.51M) | 1.46M | N/A | N/A |
| Return on Equity | -0.66 | -2.25 | -1.16 | -1.12 | -0.60 | -0.56 | -0.13 | -2.27 | N/A | -4.31 | N/A | N/A |
| Metric | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Net Income | (19.05M) | (19.87M) | (10.09M) | (9.87M) | (17.56M) | (18.66M) | (21.73M) | (17.77M) | (21.83M) | (25.17M) | (22.00M) | (25.30M) |
| EPS | -0.22 | -0.29 | -0.30 | -0.30 | -0.58 | -0.62 | -0.72 | -0.59 | -0.72 | -0.84 | -0.73 | -0.84 |
| Free Cash Flow | (15.07M) | (14.60M) | (6.72M) | (6.40M) | (18.07M) | (8.80M) | (16.66M) | (13.26M) | (13.04M) | (10.25M) | (11.63M) | (13.27M) |
| FCF / Share | -0.17 | -0.21 | -0.20 | -0.19 | -0.59 | -0.29 | -0.55 | -0.44 | -0.43 | -0.34 | -0.39 | -0.44 |
| Operating CF | (15.07M) | (14.60M) | (6.72M) | (6.40M) | (18.07M) | (8.80M) | (16.66M) | (13.26M) | (13.04M) | (10.25M) | (11.63M) | (13.27M) |
| Total Assets | 235.36M | 94.00M | 14.88M | 21.12M | 27.68M | 45.82M | 55.72M | 71.03M | 84.41M | 97.55M | 109.15M | 122.04M |
| Total Debt | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Cash & Equiv | 9.78M | 3.50M | 1.38M | 1.35M | 1.15M | 3.86M | 1.48M | 2.09M | 1.34M | 4.09M | 6.70M | 14.47M |
| Book Value | 218.73M | 86.51M | 9.47M | 15.95M | 22.44M | 35.52M | 47.63M | 61.49M | 72.05M | 85.36M | 100.73M | 111.34M |
| Return on Equity | -0.09 | -0.23 | -1.07 | -0.62 | -0.78 | -0.53 | -0.46 | -0.29 | -0.30 | -0.29 | -0.22 | -0.23 |
RLMD News
Relmada Therapeutics Q1 Earnings Call Highlights
Relmada Therapeutics, Inc. (RLMD) Q1 2026 Earnings Call Transcript
Relmada Therapeutics Reports First Quarter 2026 Financial Results and Provides Business Update
Relmada Therapeutics to Report First Quarter 2026 Financial Results on Tuesday, May 12, 2026
Relmada Therapeutics to Present NDV-01 Abstracts at AUA2026
Does Relmada Therapeutics (RLMD) Have the Potential to Rally 75.58% as Wall Street Analysts Expect?
5 Small Drug Stocks to Buy as Sector Recovery Gains Strength
Wall Street Analysts Predict a 92.19% Upside in Relmada Therapeutics (RLMD): Here's What You Should Know
Financial Contrast: Alseres Pharmaceuticals (OTCMKTS:ALSE) vs. Relmada Therapeutics (NASDAQ:RLMD)
Relmada Therapeutics, Inc. (RLMD) Q4 2025 Earnings Call Transcript